Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure TherapyGlobeNewsWire • 05/23/24
Wall Street Analysts See ResMed (RMD) as a Buy: Should You Invest?Zacks Investment Research • 05/21/24
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP TherapyGlobeNewsWire • 05/16/24
Looking for a Growth Stock? 3 Reasons Why ResMed (RMD) is a Solid ChoiceZacks Investment Research • 04/29/24
S&P 500 Gains and Losses Today: Resmed Soars Amid Strong Demand for Sleep DevicesInvestopedia • 04/26/24
ResMed Soars To Eight-Month High As Quarterly Report Wipes Out Weight-Loss WoesInvestors Business Daily • 04/26/24
ResMed Stock Soars After Strong Earnings. Wall Street Thinks It Can Do Even Better.Barrons • 04/26/24
Compared to Estimates, ResMed (RMD) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 04/25/24
ResMed (RMD) Q3 Earnings Preview: What You Should Know Beyond the Headline EstimatesZacks Investment Research • 04/22/24
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares HigherInvestors Business Daily • 04/18/24
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth SankThe Motley Fool • 04/17/24
Eli Lilly Pops After Weight-Loss Drug Succeeds In Sleep Apnea Test; ResMed DivesInvestors Business Daily • 04/17/24